MPT0B640

DB16512InvestigationalSmall molecule

MPT0B640 was under investigation in clinical trials NCT04526717 for COVID-19 infection and NCT04294875 for locally advanced or metastatic solid malignancies.

Mechanism: MPT0B640 is a heat shock protein (HSP) 90 inhibitor being developed by Joseah Bio. It is currently being investigated in oncology and against COVID-19.
Curator reviewed
Code names: MPT0B640

Resolves to

Targets

P07900HSP90AA1P08238HSP90AB1

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with MPT0B640, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account